Biotech

Biotech & Healthcare

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech

Top news of the week: 31.10.2022.

Health care
Medicine
Clinical trial
Oncology
RNA interference
Supreme Court of the United States

@brianreid shared
On Oct 27, 2022
This is a super-weird argument, economically. To avoid price controls, companies would need to price in a way that keeps Medicare sales south of $300M, give or take. I'll leave it to the economists to explain what a $300M cap would do to investment. https://t.co/jKrL0DeilB https://t.co/8iTciNmm6T
Open
Alnylam blames the Inflation Reduction Act for a PhIII cut — would it have sold enough for negotiations?

Alnylam blames the Inflation Reduction Act for a PhIII cut — would it have sold enough for negotiations?

Alnylam Pharmaceuticals, the pharma market’s leader in RNAi therapies, reported its third quarter earnings Thursday, updating shareholders on its pipeline progress and initial sales figures ...

@BIODeutschland shared
On Oct 27, 2022
RT @ITM_Radiopharma: ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs). Read the full press release at: https://t.co/IHSORLKhw1 https://t.co/yDC3uwRxN6
Open
ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)

ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)

lutetium-177 is internalized into the tumor cells and decays, releasing medical radiation (ionizing beta-radiation) with a maximum radius of 1.7 mm and destroying tumor …

@SWLifeSciences shared
On Oct 28, 2022
Nuvalent traded 60% higher to a new 52-week intraday high on initial data from its Phase 1 ARROS-1 trial of NVL-520 in ROS1-Positive non-small cell lung cancer. Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial: https://t.co/ObCT856wiB $NUVL @nuvalent
Open
Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial Trending Company

Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial Trending Company

Shares of Nuvalent Inc. traded 60% higher to a new 52-week intraday high after the company reported initial data from its Phase 1 ARROS-1 trial of NVL-520 demonstrating positive objective ...

@SWLifeSciences shared
On Oct 26, 2022
Medpace Holdings traded 37% higher yesterday after reporting Q3/22 financial results that included a nearly 30% YoY increase in revenue. CRO Firm's Shares Rise on Q3 Earnings and Growth Prospects: https://t.co/5DyeYTxgFL $MEDP @WorkatMedpace
Open
CRO Firm's Shares Rise on Q3 Earnings and Growth Prospects Trending Company

CRO Firm's Shares Rise on Q3 Earnings and Growth Prospects Trending Company

Shares of full-service clinical contract research organization Medpace Holdings Inc. traded 37% higher yesterday after the company reported Q3/22 financial results that included a nearly ...

@ldtimmerman shared
On Oct 26, 2022
Biotech executives call for action on reproductive health rights. https://t.co/HKqHKuQT9d
Open
Biotech Executives Call for Action on Reproductive Health Rights

Biotech Executives Call for Action on Reproductive Health Rights

Dear Friends and Biopharma colleagues,  The rapidly approaching midterm elections carry the potential to dramatically reshape the political landscape in myriad ways. The importance of the ...

@Alnylam shared
On Oct 27, 2022
This morning, we reported Q3 2022 financial results and highlights of recent period activity. We will host a LIVE webcast TODAY at 8:30 AM EDT to discuss and a replay will be available following. Access the webcast and replay here: https://t.co/Pz1dtBf1wv $ALNY #RNAi #siRNA
Open
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals Press Release | Oct 27, 2022

@BIODeutschland shared
On Oct 25, 2022
RT @Immutep: @Immutep is pleased to share its Annual Report with investors for the financial year 2022. #LAG3 #immunooncology $IMM $IMMP Read the report: https://t.co/4bV0WrqnLw https://t.co/WAHfjEeliY
Open
Immutep Limited

Immutep Limited

Reporting period: Year ended 30 June 2022 Previous corresponding period: Year ended 30 June 2021 ABN 90 009 237 889 Annual Report 2022 bAnnual Report 2022 Immutep Limited …

Read more:
weekly 31.10.2022
View archives
Back to home

Subscribe to Biotech - Biotech & Healthcare.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech - Biotech & Healthcare.
Privacy Policy

Sign up for the weekly Biotech - Biotech & Healthcare newsletter

Never again miss anything or anyone that matter in Biotech

Sign up and receive the Biotech - Biotech & Healthcare weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy